Perspectives

Isomorphic Labs: Engineering Biology with AI

November 17, 2026

Nearly fifty years ago, Kleiner Perkins backed Genentech on the bold idea that biology could be physically engineered. That idea started the biotech industry. We are investing in Isomorphic Labs because we believe the next era rests on an equally bold idea: that biology can be digitally engineered with AI. The need is not subtle. A new medicine still takes more than a decade and billions of dollars to reach patients, and over 90% of candidates fail. Drugs approved per research dollar have halved every nine years since 1950. We do not think this is a failure of effort. It is a failure of method. Biology is too complex to learn one experiment at a time, and the only instrument that can hold all of it is a model that learns from all of it.

It is hard to imagine a better team for this. Demis Hassabis founded Isomorphic in 2021 to take AlphaFold, his Nobel-winning work, into medicine. Around him is a world class executive team spanning frontier AI, medicinal chemistry, and clinical development, with approved drugs to their names. What strikes us most is not the credentials but the posture: AI researchers and drug hunters who treat each other’s disciplines with humility, organized around a mission as simple as it is vast: to solve all disease.

None of this was possible even five years ago. For the first time, a model can see biology at the level of atoms, predict how a molecule will behave before it is made, and learn from every experiment it runs. Drug design becomes a loop that runs at the speed of software rather than the speed of a lab. If that loop works – and the early signs are encouraging – the implications are hard to overstate. Medicines designed in months instead of years, diseases that have never had a treatment finally getting one, and an industry that compounds the way software does. 

We have rarely seen a problem this large, a team this well suited to it, and a moment this ripe. Kleiner Perkins is proud to partner with Demis, Max, and the whole Isomorphic team, with a horizon measured in decades.